These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35599598)

  • 1. VAERS-reported new-onset seizures following use of COVID-19 vaccinations as compared to influenza vaccinations.
    Avasarala J; McLouth CJ; Pettigrew LC; Mathias S; Qaiser S; Zachariah P
    Br J Clin Pharmacol; 2022 Nov; 88(11):4784-4788. PubMed ID: 35599598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
    Moro PL; Zhang B; Ennulat C; Harris M; McVey R; Woody G; Marquez P; McNeil MM; Su JR
    Vaccine; 2023 Mar; 41(11):1859-1863. PubMed ID: 36669964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Sudden Sensorineural Hearing Loss After COVID-19 Vaccination.
    Formeister EJ; Wu MJ; Chari DA; Meek R; Rauch SD; Remenschneider AK; Quesnel AM; de Venecia R; Lee DJ; Chien W; Stewart CM; Galaiya D; Kozin ED; Sun DQ
    JAMA Otolaryngol Head Neck Surg; 2022 Apr; 148(4):307-315. PubMed ID: 35201274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance systems and methods for monitoring the post-marketing safety of influenza vaccines at the Centers for Disease Control and Prevention.
    Moro PL; Li R; Haber P; Weintraub E; Cano M
    Expert Opin Drug Saf; 2016 Sep; 15(9):1175-83. PubMed ID: 27268157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System.
    Bardenheier BH; Duderstadt SK; Engler RJ; McNeil MM
    Vaccine; 2016 Aug; 34(37):4406-14. PubMed ID: 27449076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS).
    Moro PL; Ennulat C; Brown H; Woody G; Zhang B; Marquez P; Woo EJ; Su JR
    Drug Saf; 2024 May; 47(5):487-493. PubMed ID: 38411838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
    Haber P; Moro PL; Ng C; Dores GM; Lewis P; Cano M
    Vaccine; 2019 Mar; 37(11):1516-1520. PubMed ID: 30739795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
    McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R
    Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).
    Shimabukuro TT; Nguyen M; Martin D; DeStefano F
    Vaccine; 2015 Aug; 33(36):4398-405. PubMed ID: 26209838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reporting rates for VAERS death reports following COVID-19 vaccination, December 14, 2020-November 17, 2021.
    Day B; Menschik D; Thompson D; Jankosky C; Su J; Moro P; Zinderman C; Welsh K; Dimova RB; Nair N
    Pharmacoepidemiol Drug Saf; 2023 Jul; 32(7):763-772. PubMed ID: 36813704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Otorhinolaryngologic complications after COVID-19 vaccination, vaccine adverse event reporting system (VAERS).
    Shin J; Shim SR; Lee J; Ryu HS; Kim JY
    Front Public Health; 2023; 11():1338862. PubMed ID: 38269374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between seasonal influenza vaccines and the increased risk of acute disseminated encephalomyelitis, estimated using the Vaccine Adverse Event Reporting System.
    Fujimori M; Nakamura M
    Pharmazie; 2022 Sep; 77(7):262-269. PubMed ID: 36199182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety.
    Luo C; Du J; Cuker A; Lautenbach E; Asch DA; Poland GA; Tao C; Chen Y
    Sci Rep; 2022 Jun; 12(1):10946. PubMed ID: 35768434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014.
    Haber P; Moro PL; Cano M; Lewis P; Stewart B; Shimabukuro TT
    Vaccine; 2015 Apr; 33(16):1987-92. PubMed ID: 25678241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of new-onset seizures following use of COVID-19 vaccinations in children based on VAERS.
    Liu Y; He J; Zhou X; Wu Y; Cai H; Sun Y; Cui X
    Expert Opin Drug Saf; 2024 May; ():1-6. PubMed ID: 38666296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States.
    Montano D
    Front Public Health; 2021; 9():756633. PubMed ID: 35186864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.